Biogen (BIIB) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter was flat compared to the immediately preceding quarter. Compared to the same quarter one year earlier, revenue declined.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue for the quarter was flat compared to the immediately preceding quarter. Compared to the same quarter one year earlier, revenue declined.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.5B
Revenue reported for this quarter.
Quarter-over-quarter
+0.0%
Change from the immediately preceding quarter.
Year-over-year
-2.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$9.6B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $2.4B | -6.2% |
| Mar 31, 2024 | $2.3B | -7.0% |
| Jun 30, 2024 | $2.5B | +0.4% |
| Sep 30, 2024 | $2.5B | -2.5% |
Revenue performance
Reported revenue remained unchanged from the prior quarter, following a slight increase in the previous period. The year-over-year comparison shows a decrease, continuing a pattern of mixed quarterly changes.
Quarterly comparison
Revenue was level with the June quarter, which had seen a modest rise from the March quarter. The decline from the same quarter last year reflects a reversal of the prior year's comparable period performance.
What to watch
Monitor whether the flat revenue trend persists or shifts in upcoming quarters.